Atox Bio raises $23 mln to fund flesh-eating bacteria treatment: Reuters
Israel-based Atox Bio, a developer of therapeutics for severe infections, said on Thursday it has raised $23 million in an investment round led by SR One, the healthcare venture capital fund of GlaxoSmithKline.
24 July 2014•1 min read
